Phase 2bData readout

neffy® (epinephrine nasal spray)

Acute flares in patients with chronic spontaneous urticaria

SPRYARS Pharmaceuticals

Expected catalystMarch 31, 2027Company guidance: Mar 31, 2027

Catalyst overview

Event details

Drug or asset: neffy® (epinephrine nasal spray)
Development stage: Phase 2b
Event type: Data readout
Indication: Acute flares in patients with chronic spontaneous urticaria

Research signalsPotential moverHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 2b data readout for neffy® (epinephrine nasal spray) in Acute flares in patients with chronic spontaneous urticaria. The expected timing is based on the latest available company guidance and may change.

Development notes

05/15/26:- Ph2b CSU interim population fully enrolled; data expected Q4 2026; possible Ph3 start Mid-2027. 08/13/26:- Ph2b CSU interim data is expected in Q1 2027 after interim population enrollment completed.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source